JP2024533873A5 - - Google Patents
Info
- Publication number
- JP2024533873A5 JP2024533873A5 JP2024544620A JP2024544620A JP2024533873A5 JP 2024533873 A5 JP2024533873 A5 JP 2024533873A5 JP 2024544620 A JP2024544620 A JP 2024544620A JP 2024544620 A JP2024544620 A JP 2024544620A JP 2024533873 A5 JP2024533873 A5 JP 2024533873A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- composition
- item
- use according
- als
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163252061P | 2021-10-04 | 2021-10-04 | |
| US63/252,061 | 2021-10-04 | ||
| US202263301476P | 2022-01-20 | 2022-01-20 | |
| US63/301,476 | 2022-01-20 | ||
| US202263302000P | 2022-01-21 | 2022-01-21 | |
| US63/302,000 | 2022-01-21 | ||
| PCT/US2022/077557 WO2023060097A1 (en) | 2021-10-04 | 2022-10-04 | Treatment methods for als patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024533873A JP2024533873A (ja) | 2024-09-12 |
| JP2024533873A5 true JP2024533873A5 (https=) | 2025-10-14 |
Family
ID=85804736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024544620A Pending JP2024533873A (ja) | 2021-10-04 | 2022-10-04 | Ａｌｓ患者の処置方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12329776B2 (https=) |
| EP (1) | EP4412624A4 (https=) |
| JP (1) | JP2024533873A (https=) |
| AU (1) | AU2022360976A1 (https=) |
| CA (1) | CA3233863A1 (https=) |
| GB (1) | GB2626503A (https=) |
| WO (1) | WO2023060097A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017079161A2 (en) | 2015-11-02 | 2017-05-11 | Neuraltus Pharmaceuticals, Inc. | Treatment of neurodegenerative disease with sodium chlorite |
| EP4412624A4 (en) | 2021-10-04 | 2025-08-20 | Neuvivo Inc | TREATMENT METHODS FOR ALS PATIENTS |
| GB2637227A (en) | 2022-05-19 | 2025-07-16 | Neuvivo Inc | Biomarkers for neurogenerative disease |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011205095B2 (en) * | 2004-02-03 | 2014-07-03 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
| US7105183B2 (en) | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
| US20060051790A1 (en) | 2004-07-01 | 2006-03-09 | The Regents Of The University Of California | Genetic risk factor for neurodegenerative disease |
| JP5421590B2 (ja) | 2005-05-18 | 2014-02-19 | ノバルティス アーゲー | 自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法 |
| JP5371443B2 (ja) | 2005-12-22 | 2013-12-18 | ニューラルタス ファーマシューティカルズ，インコーポレイテッド | 亜塩素酸塩製剤、およびこの調製の方法と利用 |
| WO2008042190A2 (en) | 2006-09-29 | 2008-04-10 | The Trustees Of The University Of Pennsylvania | Detection of neurodegenerative disease |
| BR112012002333A2 (pt) | 2009-08-06 | 2017-07-18 | Neuraltus Pharmaceuticals Inc | método de reduzir os efeitos colaterais e método de potencializar o efeito de um imunomodulador administrado a um sujeito que dele necessita; métodos para tratar doença associada com excesso de ativação de monócitos para macrófagos ativados, diabetes tipo ii ou complicações relacionadas, doença associada com a migração de monócitos ou macrófagos ativados, doença associada a excesso de produção de scd14 e/ou scd163 por macrófagos ativados; composto de cloreto de sódio; composição farmacêutica; método para diagnosticar uma doença relacionada com macrófagos em um sujeito; e método para determinar a eficácia do tratamento com um agente oxidante para uma doença relacionada a macrófagos em um sujeito. |
| US8465727B2 (en) | 2009-10-06 | 2013-06-18 | University of Pittsburgh—of the Commonwealth System of Higher Education | Biomarkers for the diagnosis of ALS |
| JP2014081205A (ja) * | 2012-10-12 | 2014-05-08 | Fujikura Kasei Co Ltd | Ｃ−反応性タンパク質測定用の測定試薬および測定方法 |
| US20140147856A1 (en) | 2012-11-29 | 2014-05-29 | Rush University Medical Center | Intestinal Permeability Assay for Neurodegenerative Diseases |
| RU2653754C2 (ru) | 2012-12-06 | 2018-05-14 | Пин Фарма, Инк. | Лечение воспалительных, аутоиммунных и нейродегенеративных нарушений иммуннодепрессивными полипетидами, являющимися производными тат |
| CA3112130A1 (en) | 2013-07-11 | 2015-01-15 | University Of North Texas Health Science Center At Fort Worth | Blood-based screen for detecting neurological diseases in primary care settings |
| EP3116481A1 (en) * | 2014-03-13 | 2017-01-18 | Vasilios VOUDOURIS | Bendamustine solid dispersions and continuous infusion |
| EP3142674A4 (en) * | 2014-05-16 | 2018-01-17 | Neuraltus Pharmaceuticals, Inc. | Methods and compositions for treatment of macrophage-related disorders |
| WO2017079161A2 (en) | 2015-11-02 | 2017-05-11 | Neuraltus Pharmaceuticals, Inc. | Treatment of neurodegenerative disease with sodium chlorite |
| US20190060359A1 (en) | 2015-11-02 | 2019-02-28 | Neuraltus Pharmaceuticals, Inc. | Treatment of neurodegenerative disease with sodium chlorite |
| AU2022277010A1 (en) | 2021-05-18 | 2023-12-14 | Rijksuniversiteit Groningen | Nanopore proteomics |
| EP4412624A4 (en) | 2021-10-04 | 2025-08-20 | Neuvivo Inc | TREATMENT METHODS FOR ALS PATIENTS |
| JP2025518096A (ja) | 2022-05-27 | 2025-06-12 | エレドン ファーマシューティカルズ，インコーポレイテッド | 筋萎縮性側索硬化症の治療方法 |
-
2022
- 2022-10-04 EP EP22879435.0A patent/EP4412624A4/en active Pending
- 2022-10-04 JP JP2024544620A patent/JP2024533873A/ja active Pending
- 2022-10-04 AU AU2022360976A patent/AU2022360976A1/en active Pending
- 2022-10-04 WO PCT/US2022/077557 patent/WO2023060097A1/en not_active Ceased
- 2022-10-04 CA CA3233863A patent/CA3233863A1/en active Pending
- 2022-10-04 GB GB2406210.1A patent/GB2626503A/en active Pending
-
2023
- 2023-02-10 US US18/167,245 patent/US12329776B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024533873A5 (https=) | ||
| US10184931B2 (en) | Methods and systems for measuring and using the oxidation-reduction potential of a biological sample | |
| Covar et al. | Safety and application of induced sputum analysis in childhood asthma | |
| US12253531B2 (en) | Diagnostic or predictor of relapsing remitting multiple sclerosis | |
| GB2626503A (en) | Treatment methods for ALS patients | |
| Lechien et al. | Voice quality and orofacial strength as outcome of levodopa effectiveness in patients with early idiopathic Parkinson Disease: a preliminary report | |
| Drinkard et al. | Exercise capacity and idebenone intervention in children and adolescents with Friedreich ataxia | |
| JP2023549814A5 (https=) | ||
| Kang et al. | Comparison of muscle mass indices using computed tomography or dual X-ray absorptiometry for predicting physical performance in hemodialysis patients | |
| Dhanis et al. | The effect of a multimodal prehabilitation programme on preoperative physical fitness and nutritional status of women with gynaecological cancer | |
| Ferguson et al. | Shrinking lung syndrome in a 14‐year‐old boy with systemic lupus erythematosus | |
| Sakata et al. | Hermansky–Pudlak syndrome type 4 with interstitial pneumonia | |
| D’Cruz et al. | Exposing the Roots of Restriction: When the Transfer Coefficient Makes the Difference | |
| Malhotra et al. | Central sleep apnea | |
| HK40115296A (en) | Treatment methods for als patients | |
| RU2178179C1 (ru) | Способ прогнозирования течения травматической болезни головного мозга | |
| RU2267987C1 (ru) | Способ диагностики и дифференциальной диагностики бронхиальной астмы и хронической обструктивной болезни легких | |
| CN118434423A (zh) | 用于治疗舍格伦综合征或混合性结缔组织病的tlr7/8拮抗剂 | |
| JP2024534936A5 (https=) | ||
| RU2057341C1 (ru) | Способ оценки эффективности лучевой терапии рака пищевода | |
| Domínguez-González et al. | Recommendations for the diagnostic, treatment, and follow-up of late-onset Pompe disease | |
| CN115151271A (zh) | 醋酸格拉替雷在制备Aβ42毒性抑制剂和清除剂中的应用 | |
| JP2022532220A (ja) | ベンラリズマブを使用した強化された患者個体群における慢性閉塞性肺疾患を治療するための方法 | |
| Tran et al. | Neurogenic shock due to transverse myelitis with Landry’s acute flaccid paralysis in a child | |
| Wahdan et al. | Acute Tramadol Poisoning; Evaluating the Risk Factors of Seizures and Finding a Correlation with Tramadol Blood Level |